Booster shot MenQuadfi shows promise for toddlers

NCT ID NCT05929651

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether a single booster dose of the MenQuadfi vaccine is safe and effective for healthy toddlers aged 12 to 23 months who had already received a different meningococcal vaccine as infants. The 71 participants in Argentina received one shot and had blood tests before and one month after to measure immune response. The study found that the booster increased antibody levels against four types of meningococcal bacteria, with no serious safety concerns reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MenQuadfi (meningococcal conjugate vaccine)
What this could lead to
If successful, this could show that MenQuadfi is a safe and effective booster option for toddlers, helping maintain protection against meningococcal disease.
What could go wrong
This is a small, completed Phase 4 study with 71 toddlers in Argentina. Results may not apply to all populations, and the study did not compare MenQuadfi to other boosters.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational Site Number : 0320001

    Ciudad Autonoma Buenos Aires, C1425EFD, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Buenos Aires F.D., 1430, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.